Unit 4 Individual Project
Warfarin
Discovery
Warfarin is a
medication used to treat and prevent blood clots in the body. It was first used in the 1940s as a rat
poison (The History of Warfarin, n.d.), and it entered human clinical trials in
1941 at the Wisconsin General Hospital and the Mayo Clinic (The Invention of Warfarin, n.d.).
Warfarin was later approved for human consumption in 1954. It soon became a widely used rat poison, the
first and most widely used blood thinner prescribed in the world.
The Discovery of Warfarin
In the 1920s,
there was an outbreak of sweet clover disease that caused cattle to die after
mild trauma or “safe” procedures. Two veterinarians, Frank W. Schofield in
Canada and Lee M. Roderick in North Dakota discovered that eating molded hay
resulting from wet, spoiled clover was the source of the problem (The Invention of Warfarin, n.d.). Eating the hay caused the cows to hemorrhage
and bleed to death, but it was unknown which specific substance was the
culprit.
Scientists at
the University of Wisconsin continued to research the phenomena over the next
20 years. Geneticists Royal Alexander
Brink and William K. Smith researched a chemical called coumarin that makes the
clover smell sweet although it has a bitter taste. The identification of
Coumarin would be a key discovery that contributed to solving the mystery of
sweet clover disease.
In parallel
with University of Wisconsin studies, Karl Paul Link, a professor at the
University of Wisconsin, and his student assistant, Eugen Schoeffel, isolated a
substance in the clover that prevented blood from clotting, dicoumarol (The History of Warfarin, n.d.).
They later discovered that the substance was produced by a chemical reaction
between coumarin and molds that grow when clover hay gets wet and spoils. (The Invention of Warfarin, n.d.).
The researchers were awarded a patent in 1941 (Lim, 2017).
Subsequently,
University of Wisconsin colleagues Mark A. Stahmann and Charles F. Huebner
produced an identical substance in the laboratory that verified the molecule
structure. Link and the other researchers produced more than one hundred
similar compounds by varying the chemical structure. Each compound inhibited the coagulation of
the blood. The compound labeled number 42 was later named warfarin – a name
that combines the acronym “WARF”, associated with the research funding source,
the Wisconsin Alumni Research Foundation, and “arin”, derived from coumarin (The History of Warfarin, n.d.).
Warfarin was
first registered in 1948 for use as a rat poison. The sweet odor of the substance
attracted rodents while the anticoagulant property delay ensured that they were
repelled from eating the bait (Lim, 2017).
The
Accidental Discovery that Led to Warfarin Use in Humans
Although Warfarin use for humans had been considered, it was deemed too risky due to the possibility of hemorrhage. The concern was overcome due to an accident. A man who attempted suicide using the Warfarin-based rat poison was treated with vitamin K and he fully recovered! The fact that the effects of Warfarin could be reversed enabled human research that led to the approval of Warfarin for human medical use in 1954 (Lim, 2017).
Endo
Laboratories manufactured Warfarin for use by humans under the brand name Coumadin. United States President Dwight Eisenhower was an early
benefactor of the Warfarin accidental discovery. He was given the Coumadin after suffering a
heart attack. Warfarin continues to be
used to treat people and save lives.
Experts estimate that around one hundred million prescriptions of
warfarin are still issued globally each year (The Invention of Warfarin, n.d.).
Forces
that Support the Warfarin Discovery
There are
multiple forces that support the Warfarin discovery. Environmental, financial, and societal forces
initiated the chain of events that led to the Warfarin discovery. The molded clover hay was caused by the wet
climate. This environment was killing
cows that the society depended on for dairy and meat products, and that farmers
depended on for economic survival. In
1933, a desperate farmer traveled two hundred miles in a blizzard to Madison,
Wisconsin with “a milk jug full of blood, a dead cow, and a pile of moldy hay”
searching for a veterinarian and the cause of the problem (The Invention of
Warfarin, n.d.). The veterinarian was not
available when he arrived since it was the weekend, so he took the samples to a
laboratory at the University of Wisconsin where the research started.
Although
Warfarin was approved for use in rodents, societal and legislative forces
impacted its use on humans. Societal
fears about using “rat poison” to treat humans in addition to the risk of
causing hemorrhage delayed clinical trials until another “accident”
occurred. Vitamin K was used to reverse
the Warfarin effects for a man who attempted suicide using Warfarin-based
rodent poisons. This “accident”
provided knowledge that enabled Warfarin clinical trials on humans to proceed.
Technological
forces were also a key contributor to the Warfarin discovery. University of Wisconsin researchers produced
more than one hundred compounds while researching the causes of the sweet
clover disease. One of the compounds
became Warfarin.
Conclusion
There were
several accidents that led to the Warfarin discovery. Searching for a solution
for clover hay disease led to the discovery of Warfarin for use as rodent bait.
Vitamin K treatment for a Warfarin suicide attempt resulted in clinical trials
to use Warfarin to treat humans. President
Dwight Eisenhower's heart attack treatment using Warfarin provided confidence
in the medicine as a treatment in humans.
The benefits of the Warfarin discovery benefits are still impacting
lives around the world!
References
(n.d.). The
History of Warfarin. Eat On Warfarin. https://www.history.com/news/accidental-inventions#dynamite
(n.d.). The
Invention of Warfarin. ACS Chemistry for Life. https://www.acs.org/education/whatischemistry/landmarks/warfarin.html
Lim,
G. B. (2017, December 14). Warfarin: From rat poison to clinical use.
Nature Reviews Cardiology. https://www.nature.com/articles/nrcardio.2017.172
Comments
Post a Comment